Navigation Links
Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
Date:1/9/2012

BANNOCKBURN, Ill., Jan. 9, 2012  /PRNewswire/ -- Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion.

"Today's announcement represents another major milestone for Pinnacle Biologics. After completing the acquisition of the Global Photo Dynamic Therapy ("PDT") Business from Aptalis Pharma early last year, Pinnacle continues the process of solidifying its presence in the US Oncology Field, for particularly aggressive forms of cancer, expanding its presence in Europe and emerging markets, and completing the clinical work toward supporting regulatory and clinical development of new indications for PDT globally," said Guillermo Herrera, Executive Chairman and CEO of Pinnacle. In addition, the company remains focused on targeting the acquisition of other specialty pharmaceutical revenue generating products to further accelerate growth and supplement the existing business.

"Pinnacle exemplifies a new model of bio-pharmaceutical companies, with proven management, demonstrated ability to execute, and products with clear upside potential due to expansion of use in existing indications, potential for expansion into new and exciting indications in unmet clinical areas, and global expansion beyond the US and Western European markets," said Patrick Keenan, Chief Counsel and Strategist of Numoda Capital Innovations.

"The proceeds from this financing round coupled with the positive cash flows already generated by the company will be used to support Phase 3 Clinical Trials in cholangiocarcinoma, laryngeal tracheal cancer, and mesothelioma, plus the enhancement of commercial activities to optimize revenue in the current businesses of the company," said Gary Parks CFO of Pinnacle.

ABOUT PINNACLE BIOLOGICS:

Pinnacle Biologics specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. This is accomplished through licensing and acquisition of specialty pharmaceuticals and medical devices. Our innovative approach to opportunity analysis, business development, lifecycle management, regulatory expertise and distribution leverage takes each product to its highest degree of potential and maximum patient benefit.

FORWARD LOOKING STATEMENT

Except for historical information contained herein, there are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved.                                                                                               

CONTACT:

Guillermo Herrera
Executive Chairman
Pinnacle Biologics, Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695

www.pinnaclebiologics.com
www.photofrin.com


'/>"/>
SOURCE Pinnacle Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Syndication Inc. Seeks DIRECTOR OF TECHNICAL ENGINEERING for PINNACLE ENERGY - Its New Alternative Energy Subsidiary
2. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
3. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
4. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
5. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
6. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
7. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
8. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jose, CA (PRWEB) , ... January 17, 2017 , ... ... cultivate a balanced, peaceful and healthy lifestyle, announced today the official launch of its ... and frees the mind. , In development for over a year, the ...
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, a leading provider ... and performance management systems for high-consequence industries, announced today that they have entered ... sciences industry, organizations must pay much more attention to the quality of products ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, ... that it has initiated a global Phase 2b ... oral peptide that targets alpha4beta7 integrin. The aim ... is to evaluate the safety/tolerability and efficacy of ... with moderate to severe active disease. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate ... its decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. ... against DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based ...
Breaking Biology Technology:
(Date:1/4/2017)... Jan. 4, 2017  For the thousands of attendees at this year,s ... in connected health and biometric measurement devices and services, will be featuring ... On display in A&D Medical,s special CES Exhibit Suite , the ... expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):